Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 484 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; Sterile Saline Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo

NCT01612221
View directory record Official record
Conditions
Patients at Risk for Melanoma
Interventions
N-acetylcysteine, Placebo arm
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 14, 2026, 11:22 PM EDT
Withdrawn Phase 3 Interventional

Pulmozyme in Cystic Fibrosis With Sinusitis

NCT01155752
View directory record Official record
Conditions
Sinusitis, Cystic Fibrosis
Interventions
Pulmozyme single use ampule, placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01653132
View directory record Official record
Conditions
Sialorrhea
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity Trial of IHV01

NCT02756208
View directory record Official record
Conditions
HIV Infection
Interventions
300 ug FLSC vaccine, 150 ug FLSC vaccine, 75 ug FLSC vaccine, Placebo
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

NCT01181323
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

NCT01409915
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Sagramostim, Saline -- placebo comparator
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

NCT04796896
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo, mRNA-1273.214
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Months to 11 Years
Enrollment
11,942 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 14, 2026, 11:22 PM EDT
Recruiting Phase 2 Interventional

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

NCT06513949
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
Atibuclimab, Placebo
Biological · Other
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

NCT05526716
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, QIV, Matching Placebo for V116
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
56
States / cities
Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Not applicable Interventional Results available

Transversus Abdominis Plane (TAP) Block for Cesarean Section

NCT01015807
View directory record Official record
Conditions
Hyperalgesia, Secondary
Interventions
Bupivacaine Placebo, Clonidine Placebo, Bupivacaine, Clonidine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.

NCT02781818
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Epi-On Corneal Crosslinking for Keratoconus

NCT03245853
View directory record Official record
Conditions
Keratoconus, Keratoconus, Unstable
Interventions
Riboflavin 5'-Phosphate
Drug
Lead sponsor
Comprehensive EyeCare of Central Ohio
Other
Eligibility
14 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

NCT04475081
View directory record Official record
Conditions
Sepsis Syndrome
Interventions
MMR vaccine
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants

NCT06511973
View directory record Official record
Conditions
Pain, Healthy Volunteers
Interventions
Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline, A solution of 0.2% SLS
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Not applicable Interventional Results available

Viral Conjunctivitis Treatment Study

NCT03861728
View directory record Official record
Conditions
Viral Conjunctivitis
Interventions
0.01% Hypochlorous acid, Placebo
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

NCT03837756
View directory record Official record
Conditions
HIV-1-infection
Interventions
Saline, Lefitolimod, 3BNC117 and 10-1074
Drug
Lead sponsor
University of Aarhus
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 14, 2026, 11:22 PM EDT
Terminated Not applicable Interventional Results available

Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery

NCT01337739
View directory record Official record
Conditions
Pain
Interventions
Placebo Comparator, Active Comparator
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04761822
View directory record Official record
Conditions
SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Interventions
Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

NCT01513200
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Unfractionated heparin (UFH), Bendavia, Saline (0.9%, sterile, for infusion)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 14, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Results available

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

NCT02555371
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 100mg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 14, 2026, 11:22 PM EDT